secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-199931
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older
--------------------------------------------------------------------------------

- FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.
- Management targets cash flow break-even in Q4 2024 and on a full-year basis in 2025.
- Proposed combination with Greenbrook TMS Inc. remains ongoing; stockholder approval pending.
- Company presenting at William Blair 44th Annual Growth Stock Conference on August 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/0001193125-24-199931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/d835019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer